Nikko Asset Management Americas’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Nikko Asset Management Americas’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-504,201	Closed	-$37.7M	–	229
2021 Q1	$37.7M	Buy	504,201 +66,002	+15%	+$6.86M	0.18%	88
2020 Q4	$47.5M	Buy	438,199 +19,964	+5%	+$1.82M	0.27%	76
2020 Q3	$36.3M	Sell	418,235 -53,124	-11%	-$6.04M	0.32%	64
2020 Q2	$38.9M	Sell	471,359 -21,162	-4%	-$1.9M	0.51%	50
2020 Q1	$29.2M	Sell	492,521 -4,945	-1%	-$335K	0.54%	49
2019 Q4	$34.4M	Buy	497,466 +34,089	+7%	+$2.07M	0.54%	52
2019 Q3	$48.1M	Buy	463,377 +164,601	+55%	+$15.5M	0.85%	38
2019 Q2	$27.7M	Buy	298,776 +230,328	+337%	+$16M	0.54%	48
2019 Q1	$6.26M	Buy	68,448 +68,246	+33,785%	+$4.75M	0.17%	96
2018 Q4	$11K	Sell	202 -3	-1%	-$228	﹤0.01%	145
2018 Q3	$25K	Buy	+205	New	+$23.8K	﹤0.01%	144

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nikko Asset Management Americas's SYRS Position: Q2 2021 in Review

Nikko Asset Management Americas sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 504,201 shares — an estimated $37.7M sold.

Nikko Asset Management Americas first reported a position in SYRS in Q3 2018 and held it in 11 quarters. The position peaked at $48.1M in Q3 2019. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

Nikko Asset Management Americas reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Nikko Asset Management Americas sold 504,201 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $37.7M.
Nikko Asset Management Americas first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 11 quarters.
Nikko Asset Management Americas's Syros Pharmaceuticals, Inc. Common Stock position peaked at $48.1M in Q3 2019.
100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Nikko Asset Management Americas's 13F filing for Q2 2021, filed 9 Aug 2021.